登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06048926,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients with histologically confirmed locally advanced esophageal squamous cell carcinoma with a clinical stage of stage II-IVa that is inoperably resectable (including unresectable, or has contraindications to surgery or refuses surgery) (according to the 8th edition AJCC stage, the pre-treatment clinical stage is: cT1N2-3M0, cT2-4bN0-3M0);
入选标准第 3 条
Female subjects of childbearing potential should have a urine or serum pregnancy test within 72 hours prior to receiving the first study drug administration and demonstrate a negative testament,and be willing to use an effective method of contraception during the trial period to 3 months after the last dose. For male participants whose partner is a woman of childbearing age, effective methods of contraception should be used during the trial and up to three months after the last dose
入选标准第 17 条
Have received any investigational drug within 4 weeks prior to the first use of the investigational drug;
排除标准第 9 条
Participants who require systemic therapy with corticosteroids (> 10 mg prednisone equivalent per day) or other immunosuppressants within 2 weeks prior to the first study drug, except for local inflammation of the esophagus and for the prevention of allergies and nausea and vomiting. In other special circumstances, it is necessary to communicate with the sponsor. In the absence of active autoimmune disease, inhaled or topical steroid replacement and adrenocorticosteroid replacement at a dose > a potent dose of 10 mg/day prednisone is allowed;
排除标准第 10 条
Laboratory values of sodium, potassium, and calcium greater than grade 1 were abnormal in the first 2 weeks of randomization and could not be improved after treatment;
排除标准第 19 条
Any other malignancy diagnosed prior to the first use of the study drug, except for malignancies with a low risk of metastasis and death (5-year survival >90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ;
排除标准第 21 条
ECOG: 0\~1 point
入选标准第 6 条
Absolute neutrophil count (ANC) ≥1.5×109/L;
入选标准第 10 条
platelets≥ 100×109/L;
入选标准第 11 条
hemoglobin≥ 9g/dL;
入选标准第 12 条
Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or AKP≤2.5 × ULN;
入选标准第 14 条
Serum creatinine ≤1.5 × ULN or creatinine clearance ≥ 60 mL/min (calculated according to the Cockcroft-Gault formula, see Annex II);
入选标准第 15 条
International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5× ULN (can be screened for anticoagulation at a stable dose such as low molecular weight heparin or warfarin and INR within the expected therapeutic range of anticoagulants);
入选标准第 16 条
the presence of measurable and/or non-measurable lesions that meet the definition of the Efficacy Evaluation Criteria for Solid Tumors (RECIST1.1);
入选标准第 4 条
Patients with active tuberculosis infection detected by history or CT examination, or patients with a history of active tuberculosis infection within 1 year prior to enrollment, or patients with a history of active tuberculosis infection more than 1 year before that have not been formally treated;
排除标准第 17 条
a history of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation;
排除标准第 13 条
Participants had active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibodies and HCV-RNA above the lower limit of the assay);
排除标准第 18 条
pregnant or lactating women; participants of childbearing potential who are unwilling or unable to use effective contraception;
排除标准第 22 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06048926,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients voluntarily participate in this study and sign informed consent; Age 18-75 years, including 18 and 75 years old, male or female; Patients with histologically confirmed locally advanced esophageal squamous cell carcinoma with a clinical stage of stage II-IVa that is inoperably resectable (including unresectable, or has contraindications to surgery or refuses surgery) (according to the 8th edition AJCC stage, the pre-treatment clinical stage is: cT1N2-3M0, cT2-4bN0-3M0); the presence of measurable and/or non-measurable lesions that meet the definition of the Efficacy Evaluation Criteria for Solid Tumors (RECIST1.1); Have not received systemic antineoplastic therapy (including but not limited to systemic chemotherapy, molecularly targeted therapy, immunotherapy, biological therapy, topical therapy, and other investigational therapies) ECOG: 0\~1 point Fresh or archived tumor tissue samples within 6 months (fresh samples preferred) must be provided for biomarker (such as PD-L1) analysis, the sample type is FFPE tumor tissue block or at least 5 unstained, 3-5 μm thick FFPE tumor tissue section, for subjects who cannot provide tissue samples that meet the above requirements, they can discuss with the sponsor to determine whether to enroll; Expected survival≥ 3 months; The function of vital organs meets the following requirements (no blood components and cell growth factors are allowed 2 weeks before starting screening tests): Absolute neutrophil count (ANC) ≥1.5×109/L; platelets≥ 100×109/L; hemoglobin≥ 9g/dL; serum albumin≥ 2.8 g/dL; Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or AKP≤2.5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance ≥ 60 mL/min (calculated according to the Cockcroft-Gault formula, see Annex II); International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5× ULN (can be screened for anticoagulation at a stable dose such as low molecular weight heparin or warfarin and INR within the expected therapeutic range of anticoagulants); Female subjects of childbearing potential should have a urine or serum pregnancy test within 72 hours prior to receiving the first study drug administration and demonstrate a negative testament,and be willing to use an effective method of contraception during the trial period to 3 months after the last dose. For male participants whose partner is a woman of childbearing age, effective methods of contraception should be used during the trial and up to three months after the last dose排除标准:Exclusion Criteria:
history of surgery for esophageal cancer; history of previous fistula due to primary tumor invasion; a higher risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation; participants with poor nutritional status with a BMI of less than 18.5 kg/m2 or a PG-SGA score of ≥9; have undergone major surgery or severe trauma within 4 weeks prior to the first use of the study drug; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; Have received or are currently receiving any of the following treatments: Anti-PD-1 or anti-PD-L1 antibody therapy, chemotherapy, radiotherapy, targeted therapy; Have received any investigational drug within 4 weeks prior to the first use of the investigational drug; Participants who require systemic therapy with corticosteroids (> 10 mg prednisone equivalent per day) or other immunosuppressants within 2 weeks prior to the first study drug, except for local inflammation of the esophagus and for the prevention of allergies and nausea and vomiting. In other special circumstances, it is necessary to communicate with the sponsor. In the absence of active autoimmune disease, inhaled or topical steroid replacement and adrenocorticosteroid replacement at a dose > a potent dose of 10 mg/day prednisone is allowed; Those who have received an antitumor vaccine or have received a live vaccine within 4 weeks prior to the first dose of the study drug have any active autoimmune disease or history of autoimmune disease (eg, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary physitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except vitiligo or patients with asthma/allergies of the same age who have recovered and do not require any intervention in adulthood; Patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes mellitus treated with stable doses of insulin may be included; a history of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and allogeneic bone marrow transplantation; Subjects with uncontrolled cardiac clinical symptoms or diseases, such as (1) heart failure with NYHA II and above, (2) unstable angina, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention; Severe infection (CTC AE> grade 2) within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, infection comorbidities, etc. requiring hospitalization; Baseline chest imaging suggests active lung inflammation, signs and symptoms of infection present in the 2 weeks prior to first study drug use requiring oral or intravenous antibiotic therapy, except for prophylactic antibiotics; history of interstitial lung disease, noninfectious pneumonia, pulmonary fibrosis, or other uncontrolled acute lung disease; Patients with active tuberculosis infection detected by history or CT examination, or patients with a history of active tuberculosis infection within 1 year prior to enrollment, or patients with a history of active tuberculosis infection more than 1 year before that have not been formally treated; Participants had active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibodies and HCV-RNA above the lower limit of the assay); Laboratory values of sodium, potassium, and calcium greater than grade 1 were abnormal in the first 2 weeks of randomization and could not be improved after treatment; known allergy to macromolecular protein preparations, or to any carrelizul component, or allergy, hypersensitivity or contraindication to paclitaxel or cisplatin or any of the ingredients used in their preparations; Any other malignancy diagnosed prior to the first use of the study drug, except for malignancies with a low risk of metastasis and death (5-year survival >90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ; pregnant or lactating women; participants of childbearing potential who are unwilling or unable to use effective contraception; According to the investigator's judgment, the subject has other factors that may cause him to be forced to terminate the study halfway, such as other serious diseases (including psychiatric diseases) that require combined treatment, recent combination with other serious diseases (such as myocardial infarction, cerebrovascular accident) considering a high risk of recurrence, serious abnormal laboratory test values, family or social factors, which may affect the safety of subjects or the collection of trial data
引自 ClinicalTrials.gov, NCT06048926, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06048926,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。